IMPRO PRECISION (01286) achieved a total revenue of HK$1.4276 billion in the first quarter, a year-on-year increase of 22.5%.
Eagle Precision (01286) released its business and unaudited financial information for the first quarter of 2026. The group achieved a total revenue of 1.4276 billion Hong Kong dollars, a year-on-year increase of 22.5%.
IMPRO PRECISION (01286) released its business and unaudited financial information for the first quarter of 2026, with the group achieving a total revenue of HK$1.4276 billion, representing a year-on-year growth of 22.5%.
Regarding the group's quarterly sales performance and business outlook as of March 31, 2026, the Chairman and CEO, Lu Ruibo, stated: "Following the sales growth momentum from the second half of 2025, IMPRO PRECISION continued to accelerate sales growth in the first quarter of 2026. Sales in diversified industrial sectors and the aerospace, energy, and medical terminal sectors demonstrated strong resilience. In the first quarter, sales related to terminal markets in artificial intelligence data centers, including high-power engines, diversified industries, and energy, were particularly robust. Sales in the entertainment, aircraft, and engineering machinery terminal markets also saw significant growth compared to the same period last year. Although sales in the automotive sector were negative in the first quarter, the commercial vehicle market has started to recover. However, geopolitical conflicts are unpredictable, and the appreciation of the renminbi and early employment and training costs for capacity increase have brought significant challenges to the company's operations. Some terminal market customer demand is expected to strengthen in the second half of this year and in 2027, and the company is evaluating the certainty of these additional demands. Considering these factors and in combination with the current order backlog, the group has raised its full-year sales forecast for 2026 to a year-on-year growth of 15% to 20%."
Related Articles

HK Stock Market Move | SINOPHARM (01099) falls nearly 4% in the afternoon, with first quarter net profit attributable to shareholders dropping nearly 3% year-on-year.

BoC International: Three major technologies advancing together, optimistic about the potential growth space of the brain-machine interface industry.

AI cockpit volume + product going abroad: Guotai Haitong initiates PATEO (02889) with a "buy" rating, target price of HKD 236.98.
HK Stock Market Move | SINOPHARM (01099) falls nearly 4% in the afternoon, with first quarter net profit attributable to shareholders dropping nearly 3% year-on-year.

BoC International: Three major technologies advancing together, optimistic about the potential growth space of the brain-machine interface industry.

AI cockpit volume + product going abroad: Guotai Haitong initiates PATEO (02889) with a "buy" rating, target price of HKD 236.98.






